Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?

The role of the pancreatic endocannabinoid system in glucose metabolism

(2009) Francisco J. Bermúdez-Silva et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine

(2008) Andreas Artmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors

(2008) V. Di Marzo et al.   DIABETOLOGIA

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting the endocannabinoid system: to enhance or reduce?

(2008) Vincenzo Di Marzo   NATURE REVIEWS DRUG DISCOVERY

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

(2008) J. E. Lauckner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA